A medical device manufacturer has initiated a voluntary recall of over 500,000 insulin pump infusion sets after reports of intermittent flow blockages that could result in under-delivery of insulin to diabetic patients. The FDA has classified the recall as Class I, indicating the highest level of risk.
Affected patients may experience unexplained blood sugar spikes due to interrupted insulin flow. The company has established a dedicated hotline for patients to request replacement sets and is coordinating with endocrinologists to ensure continuity of care.
The FDA advises patients currently using the recalled infusion sets to monitor blood glucose levels more frequently and have backup injection supplies readily available until replacements arrive.
